ChemicalBook
Chinese english Germany Japanese Korea

Ritonavir Produkt Beschreibung

Ritonavir Struktur
155213-67-5
CAS-Nr.
155213-67-5
Englisch Name:
Ritonavir
Synonyma:
Norvi;Norvir;RITONA;CS-477;ABT-538;A 84538;Ritonavi;RITONAVIR;litonavir;NSC 693184
CBNumber:
CB0119429
Summenformel:
C37H48N6O5S2
Molgewicht:
720.94
MOL-Datei:
155213-67-5.mol

Ritonavir Eigenschaften

Schmelzpunkt:
120-122°C
Siedepunkt:
947.0±65.0 °C(Predicted)
Dichte
1.239±0.06 g/cm3(Predicted)
Flammpunkt:
2℃
storage temp. 
room temp
Löslichkeit
DMSO: soluble10mg/mL (clear solution, warmed)
Aggregatzustand
powder
pka
11.47±0.46(Predicted)
Farbe
white to beige
Wasserlöslichkeit
5mg/L(ms)
Merck 
14,8238
InChIKey
NCDNCNXCDXHOMX-XGKFQTDJSA-N
CAS Datenbank
155213-67-5(CAS DataBase Reference)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher Xi,Xn
R-Sätze: 36/38-20/21/22-41
S-Sätze: 26-37/39-36/37-39
RIDADR  UN 1648 3 / PGII
WGK Germany  3
RTECS-Nr. XA5310000
HS Code  29341000
Giftige Stoffe Daten 155213-67-5(Hazardous Substances Data)
Bildanzeige (GHS)
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H225 Flüssigkeit und Dampf leicht entzündbar. Entzündbare Flüssigkeiten Kategorie 2 Achtung P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung P264, P280, P305+P351+P338,P337+P313P
Sicherheit
P210 Von Hitze, heißen Oberflächen, Funken, offenen Flammen und anderen Zündquellenarten fernhalten. Nicht rauchen.
P261 Einatmen von Staub vermeiden.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Ritonavir Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:

R36/38:Reizt die Augen und die Haut.

S-Sätze Betriebsanweisung:

S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S37/39:Bei der Arbeit geeignete Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.

Beschreibung

Norvir was launched in Germany, the UK and US for treatment of advanced HIV in combination with antiretroviral nucleoside analogs in a record 72 days by the FDA. It is an inhibitor of HIV aspartic protease which is critical in the processing of a propeptide into the gag, gag-pol gene products and the protease itself. This inhibition results in the release of non-infectous immature virus particles. It is greater than 500-fold more selective for viral aspartic protease than the human version, has good oral bioavailability and may increase the bioavailability of other protease inhibitors. Ritonavir was able to increase the CD4 and CD8 lymphocyte count as well as reduce viral RNA. It is more potent than saqunavir and comparible in potency to zidovudine and lamivudine.Ritonavir.jpg

Beschreibung

Ritonavir is an HIV protease inhibitor. It inhibits recombinant HIV-1 protease by 79% when used at a concentration of 0.5 nM. It inhibits HIV-13B-induced cell death in MT-4 human T cell leukemia cells (EC50 = 25 nM) as well as cell death induced by HIV-1LAI, HIV-2ROD, and HIV-2EHO in human MT-2 cells (IC50s = 0.045, 0.13, and 0.24 μM, respectively). Ritonavir also inhibits the cytochrome P450 (CYP) isoform CYP3A (IC50 = 0.14 μM). It inhibits CYP-mediated oxidative metabolism of the HIV protease inhibitors saquinavir (Item No. 9001893), indinavir (Item No. 15150), nelfinavir (Item No. 15144), and amprenavir (Item No. 15369) in rat and human liver microsomes in a concentration-dependent manner. Ritonavir (10 mg/kg) also prevents decreases in plasma levels of these four compounds in rats. Formulations containing ritonavir have been used in the treatment of HIV-1 infection.

Chemische Eigenschaften

White or almost white powder.

Originator

Abbott (USA)

Verwenden

Protease inhibitor; antiviral (HIV).

Verwenden

Ritonivir is an HIV protease inhibitor (EC50 = 25 nM) that also inhibits CYP3A4, the primary cytochrome P450 isoform that metabolizes protease inhibitors. Through CYP3A4 inhibition, low doses of ritonivir can reduce the metabolism of concomitantly administered protease inhibitiors, enhancing their bioavailability and efficacy.[Cayman Chemical]

Verwenden

A selective HIV protease inhibitor

Definition

ChEBI: An L-valine derivative that is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.

Indications

Although ritonavir (Norvir) is a potent inhibitor of HIV-1 and HIV-2 protease, it is not well tolerated in higher doses. It is mainly used in low doses to increase blood levels of other protease inhibitors and to extend their dosing interval. Ritonavir is more commonly associated with gastrointestinal side effects, altered taste sensation, paresthesias, and hypertriglyceridemia than are other protease inhibitors. Pancreatitis may occur in the presence or absence of hypertriglyceridemia.

Trademarks

Norvir (Abbott).

Antimicrobial activity

Ritonavir is active against HIV-1 and, to a lesser extent, HIV-2.

Acquired resistance

At antiretroviral doses resistance is associated with the presence of specific amino acid substitutions in the HIV protease at positions 82 and 84. Concern about the risk for selection of ritonavir resistance when used at a subtherapeutic ‘booster’ dose has so far not been borne out by clinical experience.

Allgemeine Beschreibung

Ritonavir belongs to the group of protease inhibitors, which block the part of HIV called protease. Its mode of action involves binding to the protease active site and inhibiting the activity of the enzyme.

Pharmazeutische Anwendungen

A synthetic chemical available for oral use as soft capsules and a liquid formulation. It is now almost exclusively used as a pharmacokinetic enhancer to ‘boost’ the pharmacokinetic properties of HIV protease inhibitors in the treatment of HIV-1 infection in patients over 1 month in age.

Mechanism of action

Because of the strong CYP450-inhibiting effects of ritonavir, the drug has found value when used in fixed-dosage combinations with other PIs to block their metabolism and act as a booster for these drugs (lopinavir/ritonavir and tipranavir/ritonavir). In these cases, ritonavir is used in a subtherapeutic dose but boosts the effectiveness of the coadministered drug. The utilization of ritonavir in a therapeutic dose for treating HIV infections appears to be decreasing, but its utilization as a booster drug is finding favor.

Pharmakokinetik

Oral absorption: Not known/available
Cmax 600 mg twice daily: c. 11.2 mg/L
Cmin 600 mg twice daily: c. 3.7 mg/L
Plasma half-life: c. 3–5 h
Volume of distribution: c. 0.3–0.6 L/kg
Plasma protein binding: c. 97%
Absorption and distribution
Fasting and high-fat meals had no appreciable effect on oral absorption. It penetrates poorly into the CNS. The semen:plasma ratio is <0.04. It is distributed into breast milk.
Metabolism and excretion
Four oxidized metabolites have been identified, the major of which retains antiretroviral activity. Around 11% of the dose is excreted in urine, 4% as unchanged drug. The remainder is found in feces. Metabolites are eliminated primarily via the feces.
No dose adjustment is recommended in mild to moderate hepatic impairment. It should not be given to patients with severe hepatic impairment, nor should it be given as a pharmacokinetic enhancer to patients with decompensated liver disease.

Clinical Use

Treatment of HIV infection in adults and children >1 month old (in combination with other antiretroviral agents)

Nebenwirkungen

Full (antiretroviral) doses are associated with nausea, vomiting, diarrhea and fatigue in >20% of subjects. The degree to which ritonavir at low dose is associated with specific adverse events is uncertain. In HIV-negative healthy volunteers given ‘booster’ doses of 100 mg every 12 h, the concentration of total cholesterol, low-density cholesterol and triglycerides all increased, and the concentration of high-density cholesterol concentration fell.

Ritonavir Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Ritonavir Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 430)Lieferanten
Firmenname Telefon Fax E-Mail Land Produktkatalog Edge Rate
Shanghai Biolang Biotechnology Co., Ltd.
+8613397199602 +86-133-9719-9602
+8613397199602 Niky@biolang.cn China 588 58
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 968 58
Shenzhen Nexconn Pharmatechs Ltd
15013857715
admin@nexconn.com CHINA 3004 58
ShenZhen Ipure Biology import and export company co.,ltd
18071025641 18071025641
eric@ipurechemical.com CHINA 11336 58
Changsha Chemoway Imp and Exp Co.,Ltd
18942506900
+86 0731-84372166 lilyqu@chemoway.com CHINA 233 58
Hebei Senko Biotechnology Co., Ltd.
0086-133 3137 7233
christina@senko-bio.com CHINA 289 58
Shanghai Longyu Biotechnology Co., Ltd.
+8615821988213
+86 15821988213 info@longyupharma.com China 2500 58
Hangzhou Proserre Chemical Co.,Ltd.
+86-571-86088112
info@proserre.com China 1080 58
Capot Chemical Co.,Ltd.
+86(0)13336195806 +86-571-85586718
+86-571-85864795 sales@capotchem.com China 20012 60
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com China 22607 55

155213-67-5()Verwandte Suche:


  • 1,3-thiazol-5-ylmethyl n-[(2s,3s,5r)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenyl-hexan-2-yl]carbamate
  • 1,3-THIAZOL-5-YLMETHANOL
  • CHEMBRDG-BB 4050354
  • THIAZOL-5-YL-METHANOL
  • RITONAVIR
  • RARECHEM AL BD 1261
  • 1,3-Thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
  • Ritonavir for peak identification
  • litonavir
  • 1,3-Thiazol-5-ylmethyl N-[(2s,3s,5r)-3-hydroxy-5-[[(2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1
  • Ritonavir solution
  • thiazol-5-ylMethyl ((2S,3S,5R)-3-hydroxy-5-((S)-2-(3-((2-isopropylthiazol-4-yl)Methyl)-3-Methylureido)-3-MethylbutanaMido)-1,6-diphenylhexan-2-yl)carbaMate
  • Ritonavi
  • thiazol-5-ylmethyl ((2S,3S,5S)-3-hydroxy-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-yl)carbamate
  • Ritonavir, 98%, HIV protease inhibitor
  • Ritonavir(ABT-538)
  • ABT-538
  • Liponavir Core
  • (3S,4S,6S,9S)-4-Hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-2,7,10,12-tetraazatridecanoic acid, 5-thiazolylmethyl Ester
  • A 84538
  • Norvi
  • 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5S,8S,10S,11S)- (9CI)
  • 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]-
  • Abbott 84538
  • Norvir
  • NSC 693184
  • Ethinyl Estradiol, Powder
  • RITONA
  • Ritonavir Norvir
  • Ritonavir (200 mg)F0F0490.992mg/mg(ai)
  • Ritonavir (200 mg)
  • Ritonavir Related Compounds Mixture (50 mg)
  • 2,7,10,12-Tetraazatridecanoic acid, 4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3S,4S,6S,9S)-
  • CS-477
  • Ritonavire
  • 5-Thiazolylmethyl (3S,4S,6S,9S)-4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-2,7,10,12-tetraazatridecanoate
  • A 84538; ABT 538; ABBOTT 84538; NSC 693184; NORVIR; RTV
  • Ritonavir CRS
  • Ritonavir for peak identification CRS
  • 5-Thiazolylmethyl [(2S,3S,5S)-3-Hydroxy-5-[(S)-2-[3-[(2-isopropyl-4-thiazolyl)methyl]-3-methylureido]-3-methylbutanamido]-1,6-diphenyl-2-hexyl]carbamate
  • Ritonavir USP/EP/BP
  • Antiviral Agent Powder CAS 155213-67-5 Ritonavir
  • CAS 155213-67-5 Raw Steroid Powders Anti HCV Drugs 99% Ritonavir
  • Ritonavir(RTV)
  • Nirmatrelvir/Ritonavir
  • 155213-67-5
  • 115213-67-5
  • C37H48N6O5S2
  • Inhibitor
  • peptides
  • NORVIR
  • API
  • Ritonavir
  • Pharmaceutical
  • Anti-viral Compounds
  • Anti-virals
  • Inhibitors
  • Intermediates & Fine Chemicals
Copyright 2019 © ChemicalBook. All rights reserved